{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:22:55Z","timestamp":1761549775643,"version":"build-2065373602"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2010,10,21]],"date-time":"2010-10-21T00:00:00Z","timestamp":1287619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openrheumatologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORJ"],"published-print":{"date-parts":[[2010,10,21]]},"abstract":"<jats:p>\n                    <jats:italic>Context:<\/jats:italic>\n                    Fibromyalgia is a chronic musculoskeletal pain disorder. The pain can be intractable and may not respond to commonly-used treatments, such as tricyclic antidepressants and opioids.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Objectives:<\/jats:italic>\n                    To evaluate pregabalin response in the subset of patients with fibromyalgia whose pain had been judged refractory to other treatments.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Methods:<\/jats:italic>\n                    Patients had previously participated in a controlled trial of pregabalin and had moderate to severe pain despite treatment with gabapentin, a tricyclic antidepressant, and a third medication (e.g., other anticonvulsants, opioid, selective serotonin reuptake inhibitors, tramadol). Flexible-dose pregabalin 150-600 mg\/day was added for 3-month treatment cycles, each followed by 3- to 28-day pregabalin \u201cdrug holiday\u201d that lasted until a relapse occurred. Pain intensity was measured using the visual analogue scale of the Short-Form McGill Pain Questionnaire completed at baseline, the end of each 3-month treatment period and at the relapse visit. Analysis was at 15 months (after 5 cycles).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results:<\/jats:italic>\n                    In total, 25 patients were included and 19 completed the 15-month analysis period. At baseline, 88% were receiving \u22651 pain medication. Pregabalin 150-600 mg\/day was associated with statistically significant, clinically meaningful pain reduction during each treatment cycle. Pain quickly returned to baseline levels during the \u201cdrug holidays\u201d in a median time of 2-4 days. Somnolence (n=5) and dizziness (n=4) were the most common adverse events.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions:<\/jats:italic>\n                    These results suggest that pregabalin may be beneficial in patients with fibromyalgia who have had an unsatisfactory response to treatment with other medications.\n                  <\/jats:p>","DOI":"10.2174\/1874312901004010035","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T05:59:03Z","timestamp":1431583143000},"page":"35-38","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pregabalin in Treatment-Refractory Fibromyalgia"],"prefix":"10.2174","volume":"4","author":[{"given":"Brett R","family":"Stacey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birol","family":"Emir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Petersel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","first-page":"160","volume":"33","author":"Wolfe F","year":"1990","unstructured":"Wolfe F, Smythe HA, Yunus MB, et al. \n                    The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia \n                    Report of the Multicenter Criteria Committee Arthritis Rheum  \n                    1990; \n                    33\n                    : 160-72.","journal-title":"Report of the Multicenter Criteria Committee. Arthritis Rheum"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11916-001-0021-2","volume":"5","author":"White KP","year":"2001","unstructured":"White KP, Harth M. \n                    Classification, epidemiology, and natural history of fibromyalgia \n                    Curr Pain Headache Rep  \n                    2001; \n                    5\n                    : 320-9.","journal-title":"Curr Pain Headache Rep"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1472-6963-10-102","volume":"10","author":"Choy E","year":"2010","unstructured":"Choy E, Perrot S, Leon T, et al. \n                    A patient survey of the impact of fibromyalgia and the journey to diagnosis \n                    BMC Health Serv Res  \n                    2010; \n                    10\n                    : 102-0.","journal-title":"BMC Health Serv Res"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1742-1241.2007.01638.x","volume":"62","author":"Hoffman DL","year":"2008","unstructured":"Hoffman DL, Dukes EM. \n                    The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12 \n                    Int J Clin Pract  \n                    2008; \n                    62\n                    : 115-26.","journal-title":"Int J Clin Pract"},{"key":"refR5","first-page":"S67","volume":"27","author":"Salaffi F","year":"2009","unstructured":"Salaffi F, Sarzi-Puttini P, Girolimetti R, et al. \n                    Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey \n                    Clin Exp Rheumatol  \n                    2009; \n                    27\n                    : S67-74.","journal-title":"Clin Exp Rheumatol"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/AJP.0b013e3181cf599f","volume":"26","author":"Lachaine J","year":"2010","unstructured":"Lachaine J, Beauchemin C, Landry PA. \n                    Clinical and economic characteristics of patients with fibromyalgia syndrome \n                    Clin J Pain  \n                    2010; \n                    26\n                    : 284-90.","journal-title":"Clin J Pain"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1533-2500.2008.00190.x","volume":"8","author":"Perrot S","year":"2008","unstructured":"Perrot S, Dickenson AH, Bennett RM. \n                    Fibromyalgia: harmonizing science with clinical practice considerations \n                    Pain Pract  \n                    2008; \n                    8\n                    : 177-89.","journal-title":"Pain Pract"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1001\/jama.292.19.2388","volume":"292","author":"Goldenberg DL","year":"2004","unstructured":"Goldenberg DL, Burckhardt C, Crofford L. \n                    Management of fibromyalgia syndrome \n                    JAMA  \n                    2004; \n                    292\n                    : 2388-95.","journal-title":"JAMA"},{"key":"refR9","first-page":"16","volume":"11","author":"Briley M","year":"2010","unstructured":"Briley M. \n                    Drugs to treat fibromyalgia - the transatlantic difference \n                    Curr Opin Investig Drugs  \n                    2010; \n                    11\n                    : 16-8.","journal-title":"Curr Opin Investig Drugs"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.0409066103","volume":"103","author":"Field MJ","year":"2006","unstructured":"Field MJ, Cox PJ, Stott E, et al. \n                    Identification of the \u03b12-\u03b3-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin \n                    Proc Natl Acad Sci USA  \n                    2006; \n                    103\n                    : 17537-42.","journal-title":"Proc Natl Acad Sci USA"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","volume":"52","author":"Crofford LJ","year":"2005","unstructured":"Crofford LJ, Rowbotham MC, Mease PJ, et al. \n                    Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial \n                    Arthritis Rheum  \n                    2005; \n                    52\n                    : 1264-73.","journal-title":"Arthritis Rheum"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","volume":"9","author":"Arnold LM","year":"2008","unstructured":"Arnold LM, Russell IJ, Diri EW, et al. \n                    A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia \n                    J Pain  \n                    2008; \n                    9\n                    : 792-05.","journal-title":"J Pain"},{"key":"refR13","first-page":"502","volume":"35","author":"Mease PJ","year":"2008","unstructured":"Mease PJ, Russell IJ, Arnold LM, et al. \n                    A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia \n                    J Rheumatol  \n                    2008; \n                    35\n                    : 502-14.","journal-title":"J Rheumatol"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pain.2008.02.027","volume":"136","author":"Crofford LJ","year":"2008","unstructured":"Crofford LJ, Mease PJ, Simpson SL, et al. \n                    Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin \n                    Pain  \n                    2008; \n                    136\n                    : 419-31.","journal-title":"Pain"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11916-006-0043-x","volume":"10","author":"Stacey BR","year":"2006","unstructured":"Stacey BR, Swift JN. \n                    Pregabalin for neuropathic pain based on recent clinical trials \n                    Curr Pain Headache Rep  \n                    2006; \n                    10\n                    : 179-84.","journal-title":"Curr Pain Headache Rep"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","volume":"30","author":"Melzack R","year":"1987","unstructured":"Melzack R. \n                    The short-form McGill pain questionnaire \n                    Pain  \n                    1987; \n                    30\n                    : 191-97.","journal-title":"Pain"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.1526-4637.2008.00423.x","volume":"9","author":"Stacey BR","year":"2008","unstructured":"Stacey BR, Dworkin RH, Murphy K, Sharma U, Emir B, Griesing T. \n                    Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial \n                    Pain Med  \n                    2008; \n                    9\n                    : 1202-8.","journal-title":"Pain Med"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"Farrar JT","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. \n                    Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale \n                    Pain  \n                    2001; \n                    94\n                    : 149-58.","journal-title":"Pain"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/art.10225","volume":"46","author":"Gracely RH","year":"2002","unstructured":"Gracely RH, Petzke F, Wolf JM, Clauw DJ. \n                    Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia \n                    Arthritis Rheum  \n                    2002; \n                    46\n                    : 1333-43.","journal-title":"Arthritis Rheum"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/16501960310010215","volume":"41","author":"Henriksson KG","year":"2003","unstructured":"Henriksson KG. \n                    Fibromyalgia--from syndrome to disease. Overview of pathogenetic mechanisms \n                     J Rehabil Med  \n                    2003; \n                    41\n                    (Suppl)\n                    : 89-94.","journal-title":"J Rehabil Med"},{"key":"refR21","author":"Tuchman M","year":"2010","unstructured":"Tuchman M, Barrett JA, Donevan S, Hedberg TG, Taylor CP. \n                    Central sensitization and Ca(V)alpha(2)delta ligands in chronic pain syndromes: pathologic processes and pharmacologic effect \n                    J Pain May 14 \n                    2010.","journal-title":"J Pain. May 14"},{"key":"refR22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.2007.071522","volume":"67","author":"Carville SF","year":"2008","unstructured":"Carville SF, Arendt-Nielsen S, Bliddal H, et al. \n                    EULAR evidence-based recommendations for the management of fibromyalgia syndrome \n                    Ann Rheum Dis  \n                    2008; \n                    67\n                    : 536-41.","journal-title":"Ann Rheum Dis"}],"container-title":["The Open Rheumatology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V4\/TORJ-4-35\/TORJ-4-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V4\/TORJ-4-35\/TORJ-4-35.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V4\/TORJ-4-35\/TORJ-4-35.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:20:01Z","timestamp":1761549601000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrheumatologyjournal.com\/VOLUME\/4\/PAGE\/35\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,21]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,10,21]]}},"alternative-id":["TORJ-4-35"],"URL":"https:\/\/doi.org\/10.2174\/1874312901004010035","relation":{},"ISSN":["1874-3129"],"issn-type":[{"type":"print","value":"1874-3129"}],"subject":[],"published":{"date-parts":[[2010,10,21]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2010-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-06-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}